(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 May 2012 (18.05.2012)

PCT

(10) International Publication Number
WO 2012/062783 A1

(51) International Patent Classification:
*C07D 401/14* (2006.01) *C07D 413/14* (2006.01)
*C07D 403/12* (2006.01) *A61K 31/506* (2006.01)
*C07D 403/14* (2006.01) *A61P 25/16* (2006.01)
*C07D 405/14* (2006.01)

(21) International Application Number:
PCT/EP2011/069696

(22) International Filing Date:
9 November 2011 (09.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/412,273 10 November 2010 (10.11.2010) US
61/546,613 13 October 2011 (13.10.2011) US

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BAKER-GLENN, Charles** [GB/GB]; c/o BioFocus, Chesterford Research Park, Saffron Walden, Essex CB10 1XL (GB). **BURDICK, Daniel Jon** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **CHAMBERS, Mark** [GB/GB]; c/o BioFocus, Chesterford Research Park, Saffron Walden, Essex CB10 1XL (GB). **CHEN, Huifen** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **ESTRADA, Anthony** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **SWEENEY, Zachary Kevin** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **CHAN, Bryan K.** [CA/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US).

(74) Agent: **MUELLER-AFRAZ, Simona**; Grenzacherstrasse 124, CH-4070 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

(54) Title: PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS




(I)

(57) Abstract: Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein X, $R^1$, $R^2$, $R^3$, $R^4$ and $R^5$ are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

WO 2012/062783 A1